Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22308421 | 0.85 | DPP4 (0.33) | NFKB1NFKB2RELAASGR1HDAC6 | |
| SCHEMBL3714007 | 0.82 | EPHX1 (0.34) | NFKB1NFKB2RELAHSD11B1 | |
| SCHEMBL2822608 | 0.81 | HDAC6 (0.33) | NFKB1NFKB2RELAHDAC6KDM1A | |
| SCHEMBL23145359 | 0.80 | — | — | |
| SCHEMBL13052389 | 0.79 | CHRM2 (0.34) | NFKB1NFKB2RELAASGR1HDAC6 | |
| SCHEMBL14327679 | 0.79 | CHRM2 (0.34) | NFKB1NFKB2RELAASGR1HDAC6 | |
| SCHEMBL13052392 | 0.78 | NFKB1 (0.32) | NFKB1NFKB2RELAHDAC6HDAC1 | |
| SCHEMBL21274075 | 0.74 | HSD11B1 (0.41) | NFKB1NFKB2RELAMT-CO2ASGR1 | |
| SCHEMBL13052385 | 0.72 | PPM1D (0.32) | — | |
| SCHEMBL16322241 | 0.70 | CCR5 (0.37) | NFKB1NFKB2RELAMT-CO2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4053126-B1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | BROADENBIO CO., LTD. (CN) | 2025-07-01 | — | — | US | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | BROADENBIO CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4053126-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083011-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF | 北京伯汇生物技术有限公司 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344611-B2 | Bridged cycloformylpyridine derivatives and uses thereof | FGFR4, FGFR1, FGFR3 | NFKB1 4101/4885NFKB2 4392/4885RELA 4562/4885 |
| US-20230012600-A1 | BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF | FGFR4, FGFR1, FGFR3 | NFKB1 4101/4885NFKB2 4392/4885RELA 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.